Table 2.
Trials using a combination of PARPi and anti-angiogenic agents.
| Study name (NCT number) | Treatment setting | Patient population | Drug name | PFS PARPi versus placebo (months) | HR (95% CI) |
|---|---|---|---|---|---|
| PAOLA-1 (NCT02477644) 8 | First-line maintenance | All comers | Olaparib plus bevacizumab | Overall: 22.1 versus
16.6 gBRCA1/2 mut: 37.2 versus 17.7 HRD & BRCA1/2 wt: 28.1 versus 16.6 HRD test neg: 16.9 versus 16.0 |
0.59 (0.49–0.72) 0.33 (0.25–0.45) 0.43 (0.28–0.66) 0.92 (0.72–1.17) |
| AVANOVA-2 (NCT02354131) 9 | PSR maintenance | All comers | Niraparib plus bevacizumab | 11.9 versus 5.5 | 0.35 (0.21–0.57) |
| OVARIO (NCT03326193) 10 | First-line maintenance | All comers | Niraparib plus bevacizumab | Overall: 19.6 (no placebo arm) HRD: 28.3 HRD test neg: 14.2 |
n/a |
| NCT0111664811 | PSR maintenance | All comers | Olaparib plus cedirinib | Overall: 16.5 versus
8.2 gBRCA1/2 mut: 16.4 versus 16.5 gBRCA1/2 wt: 23.7 versus 5.7 |
0.50 (0.30–0.83) 0.76 (0.38–1.49) 0.31 (0.15–0.66) |
| ICON9 (NCT03278717) 12 | PSR maintenance | All comers | Olaparib plus cedirinib | Trial ongoing | n/a |
BRCA1/2 mut, BRCA1/2 mutation carriers; CI, confidence interval; g, germline; HR, hazard ratio; HRD, homologous recombination deficient; PARPi, PARP inhibitors; PFS, progression-free survival; PSR, platinum-sensitive relapse; wt, wild-type.